

FLORIDA MEDICAID PRIOR AUTHORIZATION

HEPATITIS C AGENTS

Note: Form must be completed in full.

An in	comple	ete fo	rm ma	ay be	retu	irned.
-------	--------	--------	-------	-------	------	--------

Recipient's Medicaid ID#	Date of Birth (MM/DD/YYYY)
Recipient's Full Name	
Prescriber's Full Name	
Prescriber License # (ME, OS, ARNP, PA)	
Prescriber Phone Number	Prescriber Fax Number
What is/are the requested medication(s)?	
□ Sovaldi weeks □ □ Olysio weeks □ □ Harvoni weeks □ □ Technivie weeks □	DaklinzaweeksRibavirin*weeksPeginterferon alfa**weeksZepatierweeksOtherweeks
*Ribavirin: Provide drug, strength, and directions:	
**Peginterferon alfa: Provide drug, strength and direction	NS:

(If prescribing non-preferred alternatives, please provide documentation of a medical reason why the patient is unable to take the preferred medication)

PLEASE NOTE: VIEKIRA IS THE PREFERRED AGENT FOR GENOTYPE 1. IF THE DIAGNOSIS IS ON FILE, THE RECEIPIENT IS 18 YEARS OR OLDER AND IS TREATMENT NAÏVE, THE CLAIM WILL PAY FOR 12 WEEKS OF THERAPY WITHOUT A PRIOR AUTHORIZATION

<u>Ph</u>	ysician must submit all supporting documentation includi	ng lab results.					
1.	Does the recipient have chronic hepatitis C?					🗌 Yes	🗌 No
2.	Is prescriber a hepatologist, gastroenterologist, infectious disease sp	pecialist, or transp	plant phys	sician?		🗌 Yes	🗌 No
3.	If no, is the prescribing physician in consultation with a specialist ind	icated above?				🗌 Yes	🗌 No
4.	 What is the recipient's HCV genotype? (attach genotype test results) If genotype 1a, NS3 Q80K polymorphism? (simeprevir requests) If genotype 1a, please list any NS5A polymorphisms: (must sub) 	only)		3	4	☐ 5 ☐ Yes	□ 6 □ No
		M28	Q30		🗌 L31		☐ Y93
5.	Has the recipient been previously treated with HCV therapy? If yes, please specify date, regimen and duration:					🗌 Yes	🗌 No
	If yes, please document response to therapy:	Null respond	ler 🗌 P	artial res	ponder	🗌 Rela	pser



FLORIDA MEDICAID PRIOR AUTHORIZATION

HEPATITIS C AGENTS

Note: Form must be completed in full. An incomplete form may be returned. ed.

An	Inco	omp	iete	torm	may	be	retu	rneo

6. Does	the recipient have chronic HCV with cirrh	osis? (supporting documentation re	quired)	🗌 Yes 🗌 No
If cirrh	nosis, what type?	Compens	ated Decompensated	
7. Child	Pugh Score:		A	□в □с
8. Does	the recipient have hepatocellular carcino	ma?		🗌 Yes 🗌 No
	recipient HIV co-infected? have documented diagnosis and must su	bmit most recent CD4 count – within	last 6 months)	🗌 Yes 🗌 No
10. Liver t	transplant? (If yes, please specify date a	nd submit supporting documentation	n)	
Ľ	Awaiting liver transplant (date):	No	Post-transplant	
11. Indica	te HCV RNA level <i>(must submit lab resu</i>	Its within the past three months for l	paseline).	
	Treatment week	Log10	Date Measure	d
	Pre-treatment baseline			
inclus 13. For rit	ne recipient committed to the documenter ive of anticipated blood tests and physici pavirin therapy: If the patient is a female of ancy test within 30 days of initiating thera	an visits, during and after treatment of childbearing potential, has a nega	tive	□Yes □No □Yes □No
	ecipient abstained from illicit drugs and/o submit results of test)	r alcohol consumption for a minimur	n of 1 month?	🗌 Yes 🗌 No
OR				
	recipient receiving substance or alcohol submit supporting documentation)	abuse counseling services?		🗌 Yes 🗌 No
By signing	below, the prescriber attests that all stat	ements provided are accurate.		
Prescriber	Signature:	Date:		



Pharmacy Provider Services Fax: 855-825-2717 Phone: 1-800-617-5727